Working capital decreased 25.3%
Working capital changed -25.3% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Working capital changed -25.3% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Working capital / assets changed -1335 basis points from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Operating income changed +187.1% from the comparable as-filed period.
Operating margin changed +534 basis points from the comparable as-filed period.
Shares outstanding changed -15.7% from the comparable as-filed period. The change ranks at the 88th percentile of 8 prior comparable changes.
Total assets changed +7.5% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Cash & equivalents changed -31.2% from the comparable as-filed period.
SBC / revenue changed -780 basis points from the comparable as-filed period.
Stock-based compensation changed -36.5% from the comparable as-filed period.
Net income changed -18.7% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Capital expenditure changed +154.7% from the comparable as-filed period.
Gross margin changed -71 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Current assets changed -13.8% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Operating cash flow changed +8.7% from the comparable as-filed period.
Operating cash flow / net income changed +33.8% from the comparable as-filed period.
Capex / revenue changed +108 basis points from the comparable as-filed period.
Free-cash-flow proxy changed +4.9% from the comparable as-filed period.
Revenue changed +0.8% from the comparable as-filed period.
Operating cash-flow margin changed +216 basis points from the comparable as-filed period.
Current ratio changed -15.6% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Current liabilities changed +2.2% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes. This reverses 2 consecutive comparable moves in the opposite direction.
Receivables / revenue changed +60 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Free-cash-flow margin changed +108 basis points from the comparable as-filed period.
Gross profit changed -0.0% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
R&D / revenue changed -21 basis points from the comparable as-filed period.
Trade receivables changed +1.9% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Research & development changed +0.0% from the comparable as-filed period.
Cost of revenue changed +5.5% from the comparable as-filed period.
Stock-based compensation changed -30.2% from the comparable as-filed period.
Operating margin changed +1621 basis points from the comparable as-filed period.
Operating income changed +188.9% from the comparable as-filed period.
Operating cash flow changed +44.4% from the comparable as-filed period. The change ranks at the 67th percentile of 6 prior comparable changes.
Revenue changed +1.0% from the comparable as-filed period.
Free-cash-flow proxy changed +43.3% from the comparable as-filed period. The change ranks at the 67th percentile of 6 prior comparable changes.
Cash & equivalents changed -43.8% from the comparable as-filed period.
Capital expenditure changed +118.8% from the comparable as-filed period. The change ranks at the 100th percentile of 6 prior comparable changes.
Net income changed +173.8% from the comparable as-filed period.
Gross profit changed +1.3% from the comparable as-filed period.
Gross margin changed +29 basis points from the comparable as-filed period.
Research & development changed -11.9% from the comparable as-filed period.
Capex / revenue changed +43 basis points from the comparable as-filed period.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.